Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Fundamental Analysis
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (T14.SI) shows strong financial fundamentals with a PE ratio of 7.94, profit margin of 43.38%, and ROE of 25.74%. The company generates $9.6B in annual revenue with weak year-over-year growth of -11.14%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 52.4/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze T14.SI's fundamental strength across five key dimensions:
Efficiency Score
ExcellentT14.SI demonstrates superior asset utilization.
Valuation Score
ExcellentT14.SI trades at attractive valuation levels.
Growth Score
WeakT14.SI faces weak or negative growth trends.
Financial Health Score
ExcellentT14.SI maintains a strong and stable balance sheet.
Profitability Score
ExcellentT14.SI achieves industry-leading margins.
Key Financial Metrics
Is T14.SI Expensive or Cheap?
P/E Ratio
T14.SI trades at 7.94 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, T14.SI's PEG of -0.03 indicates potential undervaluation.
Price to Book
The market values Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited at 2.38 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 13.70 times EBITDA. This signals the market has high growth expectations.
How Well Does T14.SI Make Money?
Net Profit Margin
For every $100 in sales, Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited keeps $43.38 as profit after all expenses.
Operating Margin
Core operations generate 49.53 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $25.74 in profit for every $100 of shareholder equity.
ROA
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited generates $18.23 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited generates limited operating cash flow of $930.19M, signaling weaker underlying cash strength.
Free Cash Flow
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited produces free cash flow of $696.72M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.46 in free cash annually.
FCF Yield
T14.SI converts 1.07% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
7.94
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.03
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.38
vs 25 benchmark
P/S Ratio
Price to sales ratio
6.76
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.009
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.59
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.26
vs 25 benchmark
ROA
Return on assets percentage
0.18
vs 25 benchmark
ROCE
Return on capital employed
0.34
vs 25 benchmark
How T14.SI Stacks Against Its Sector Peers
| Metric | T14.SI Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 7.94 | 28.45 | Better (Cheaper) |
| ROE | 25.74% | 763.00% | Weak |
| Net Margin | 43.38% | -45266.00% (disorted) | Strong |
| Debt/Equity | 0.01 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 1.59 | 2795.60 | Neutral |
| ROA | 18.23% | -16586.00% (disorted) | Strong |
T14.SI outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
4.30%
Industry Style: Defensive, Growth, Innovation
GrowingEPS CAGR
255.77%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
86.31%
Industry Style: Defensive, Growth, Innovation
High Growth